Premium
Pyridazine derivatives as novel acyl‐coa:cholesterol acyltransferase (acat) inhibitors
Author(s) -
Gelain Arianna
Publication year - 2005
Publication title -
journal of heterocyclic chemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.321
H-Index - 59
eISSN - 1943-5193
pISSN - 0022-152X
DOI - 10.1002/jhet.5570420306
Subject(s) - sterol o acyltransferase , chemistry , acyl coa , cholesterol , enzyme , acylation , biochemistry , pyridazine , acyltransferases , medicine , stereochemistry , biosynthesis , lipoprotein , catalysis
Acyl‐CoA:cholesterol acyltransferase (E.C.2.3.1.26, ACAT) is a microsomial enzyme that catalyses the formation of cholesteryl esters by acylation of cholesterol with long chain fatty acylCoA [1]. ACAT plays important roles in cellular homeostasis and in the early stages of atherosclerosis. Therefore, ACAT inhibitors have been identified as useful agents in the treatment of hypercholesterolemia, atherosclerosis and coronary diseases [2]. In addition, recently their application has been proposed for Alzheimer's disease [3].